{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T05:06:20Z","timestamp":1741496780745,"version":"3.38.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,8]]},"DOI":"10.7759\/cureus.80257","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T17:33:37Z","timestamp":1741455217000},"source":"Crossref","is-referenced-by-count":0,"title":["Cutaneous Adverse Events Following COVID-19 Vaccination in Japan: A Questionnaire Survey"],"prefix":"10.7759","author":[{"given":"Yuto","family":"Yamamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisa","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Kawahira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Fuyuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Tsuruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riichiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin'Ichi","family":"Imafuku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Corona virus: a review of Covid-19","volume":"4","author":"Kumar D","year":"2020","unstructured":"Kumar D, Malviya R, Sharma PK. Corona virus: a review of Covid-19. Eurasian J Med Oncol. 2020, 4:8-25.","journal-title":"Eurasian J Med Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.12.03073","article-title":"COVID-19 in Japan during 2020-2022: characteristics, responses, and implications for the health care system","volume":"12","author":"Karako K","year":"2022","unstructured":"Karako K, Song P, Chen Y, Karako T. COVID-19 in Japan during 2020-2022: characteristics, responses, and implications for the health care system. J Glob Health. 2022, 12:03073. 10.7189\/jogh.12.03073","journal-title":"J Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1790","article-title":"Developing a vaccine for COVID-19","volume":"369","author":"Caddy S","year":"2020","unstructured":"Caddy S. Developing a vaccine for COVID-19. BMJ. 2020, 369:m1790. 10.1136\/bmj.m1790","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.2022.J012","article-title":"Effectiveness of mRNA COVID-19 vaccines in Japan during the nationwide pandemic of the Delta variant","volume":"257","author":"Akaishi T","year":"2022","unstructured":"Akaishi T, Kushimoto S, Katori Y, et al.. Effectiveness of mRNA COVID-19 vaccines in Japan during the nationwide pandemic of the Delta variant. Tohoku J Exp Med. 2022, 257:1-6. 10.1620\/tjem.2022.J012","journal-title":"Tohoku J Exp Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12291-021-00968-z","article-title":"Adverse events reported from COVID-19 vaccine trials: a systematic review","volume":"36","author":"Kaur RJ","year":"2021","unstructured":"Kaur RJ, Dutta S, Bhardwaj P, et al.. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021, 36:427-39. 10.1007\/s12291-021-00968-z","journal-title":"Indian J Clin Biochem"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S388245","article-title":"Cutaneous reactions following COVID-19 vaccination: a review of the current literature","volume":"15","author":"Martora F","year":"2022","unstructured":"Martora F, Battista T, Marasca C, Genco L, Fabbrocini G, Potestio L. Cutaneous reactions following COVID-19 vaccination: a review of the current literature. Clin Cosmet Investig Dermatol. 2022, 15:2369-82. 10.2147\/CCID.S388245","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17188","article-title":"Cutaneous adverse events following COVID-19 vaccination: a case series of 30 Japanese patients and a review of 93 Japanese studies","volume":"51","author":"Baba A","year":"2024","unstructured":"Baba A, Yamada K, Kanekura T. Cutaneous adverse events following COVID-19 vaccination: a case series of 30 Japanese patients and a review of 93 Japanese studies. J Dermatol. 2024, 51:827-38. 10.1111\/1346-8138.17188","journal-title":"J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.03.055","article-title":"\"COVID arm\": very delayed large injection site reactions to mRNA COVID-19 vaccines","volume":"9","author":"Ramos CL","year":"2021","unstructured":"Ramos CL, Kelso JM. \"COVID arm\": very delayed large injection site reactions to mRNA COVID-19 vaccines. J Allergy Clin Immunol Pract. 2021, 9:2480-1. 10.1016\/j.jaip.2021.03.055","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2102131","article-title":"Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2","volume":"384","author":"Blumenthal KG","year":"2021","unstructured":"Blumenthal KG, Freeman EE, Saff RR, et al.. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med. 2021, 384:1273-7. 10.1056\/NEJMc2102131","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/v15071585","article-title":"How infection and vaccination are linked to acute and chronic urticaria: a special focus on COVID-19","volume":"15","author":"Kocat\u00fcrk E","year":"2023","unstructured":"Kocat\u00fcrk E, Mu\u00f1oz M, Elieh-Ali-Komi D, et al.. How infection and vaccination are linked to acute and chronic urticaria: a special focus on COVID-19. Viruses. 2023, 15:1585. 10.3390\/v15071585","journal-title":"Viruses"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2022.43.210101","article-title":"Delayed systemic urticarial reactions following mRNA COVID-19 vaccination","volume":"43","author":"Pitlick MM","year":"2022","unstructured":"Pitlick MM, Joshi AY, Gonzalez-Estrada A, Chiarella SE. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination. Allergy Asthma Proc. 2022, 43:40-3. 10.2500\/aap.2022.43.210101","journal-title":"Allergy Asthma Proc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2022.43.210111","article-title":"Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2","volume":"43","author":"Magen E","year":"2022","unstructured":"Magen E, Yakov A, Green I, Israel A, Vinker S, Merzon E. Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2. Allergy Asthma Proc. 2022, 43:30-6. 10.2500\/aap.2022.43.210111","journal-title":"Allergy Asthma Proc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-023-03366-w","article-title":"Henoch-Schonlein purpura following exposure to SARS-CoV2 vaccine or infection: a systematic review and a case report","volume":"19","author":"Di Vincenzo F","year":"2024","unstructured":"Di Vincenzo F, Ennas S, Pizzoferrato M, Bibb\u00f2 S, Porcari S, Ianiro G, Cammarota G. Henoch-Schonlein purpura following exposure to SARS-CoV2 vaccine or infection: a systematic review and a case report. Intern Emerg Med. 2024, 19:13-37. 10.1007\/s11739-023-03366-w","journal-title":"Intern Emerg Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06694-6","article-title":"New-onset systemic vasculitis following SARS-CoV-2 infection and vaccination: the trigger, phenotype, and outcome","volume":"42","author":"Mv P","year":"2023","unstructured":"Mv P, Auanassova A, Yessirkepov M, Zimba O, Gasparyan AY, Kitas GD, Ahmed S. New-onset systemic vasculitis following SARS-CoV-2 infection and vaccination: the trigger, phenotype, and outcome. Clin Rheumatol. 2023, 42:2761-75. 10.1007\/s10067-023-06694-6","journal-title":"Clin Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1013846","article-title":"Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination","volume":"9","author":"Corr\u00e0 A","year":"2022","unstructured":"Corr\u00e0 A, Verdelli A, Mariotti EB, et al.. Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination. Front Med (Lausanne). 2022, 9:1013846. 10.3389\/fmed.2022.1013846","journal-title":"Front Med (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.153834","article-title":"Autoimmune mucocutaneous blistering diseases after SARS-CoV-2 vaccination: a case report of Pemphigus vulgaris and a literature review","volume":"232","author":"Calabria E","year":"2022","unstructured":"Calabria E, Canfora F, Mascolo M, Varricchio S, Mignogna MD, Adamo D. Autoimmune mucocutaneous blistering diseases after SARS-CoV-2 vaccination: a case report of Pemphigus vulgaris and a literature review. Pathol Res Pract. 2022, 232:153834. 10.1016\/j.prp.2022.153834","journal-title":"Pathol Res Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/v15071423","article-title":"The impact of COVID-19 vaccination on inflammatory skin disorders and other cutaneous diseases: a review of the published literature","volume":"15","author":"Martora F","year":"2023","unstructured":"Martora F, Battista T, Ruggiero A, Scalvenzi M, Villani A, Megna M, Potestio L. The impact of COVID-19 vaccination on inflammatory skin disorders and other cutaneous diseases: a review of the published literature. Viruses. 2023, 15:1423. 10.3390\/v15071423","journal-title":"Viruses"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00715-x","article-title":"Curbing COVID-19 vaccine hesitancy from a dermatological standpoint: analysis of cutaneous reactions in the Vaccine Adverse Event Reporting System (VAERS) database","volume":"23","author":"Falotico JM","year":"2022","unstructured":"Falotico JM, Desai AD, Shah A, Ricardo JW, Lipner SR. Curbing COVID-19 vaccine hesitancy from a dermatological standpoint: analysis of cutaneous reactions in the Vaccine Adverse Event Reporting System (VAERS) database. Am J Clin Dermatol. 2022, 23:729-37. 10.1007\/s40257-022-00715-x","journal-title":"Am J Clin Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18294","article-title":"Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: a systematic review and meta-analysis","volume":"36","author":"Washrawirul C","year":"2022","unstructured":"Washrawirul C, Triwatcharikorn J, Phannajit J, Ullman M, Susantitaphong P, Rerknimitr P. Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2022, 36:1947-68. 10.1111\/jdv.18294","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15391","article-title":"Cutaneous adverse reactions of COVID-19 vaccines: a systematic review","volume":"35","author":"Qaderi K","year":"2022","unstructured":"Qaderi K, Golezar MH, Mardani A, et al.. Cutaneous adverse reactions of COVID-19 vaccines: a systematic review. Dermatol Ther. 2022, 35:e15391. 10.1111\/dth.15391","journal-title":"Dermatol Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16063","article-title":"SARS-CoV-2 vaccine-related cutaneous manifestations: a\u2009systematic review","volume":"61","author":"Avallone G","year":"2022","unstructured":"Avallone G, Quaglino P, Cavallo F, Roccuzzo G, Ribero S, Zalaudek I, Conforti C. SARS-CoV-2 vaccine-related cutaneous manifestations: a\u2009systematic review. Int J Dermatol. 2022, 61:1187-204. 10.1111\/ijd.16063","journal-title":"Int J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15894","article-title":"Atypical erythema multiforme related to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine","volume":"60","author":"Buj\u00e1n Bonino C","year":"2021","unstructured":"Buj\u00e1n Bonino C, Moreiras Arias N, L\u00f3pez-Pardo Rico M, Pita da Veiga Seijo G, Ros\u00f3n L\u00f3pez E, Su\u00e1rez Pe\u00f1aranda JM, S\u00e1nchez-Aguilar Rojas D. Atypical erythema multiforme related to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. Int J Dermatol. 2021, 60:e466-7. 10.1111\/ijd.15894","journal-title":"Int J Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2023.12.2.87","article-title":"Occurrence of erythema multiforme following COVID-19 vaccination: a review","volume":"12","author":"Yousefian M","year":"2023","unstructured":"Yousefian M, Khadivi A. Occurrence of erythema multiforme following COVID-19 vaccination: a review. Clin Exp Vaccine Res. 2023, 12:87-96. 10.7774\/cevr.2023.12.2.87","journal-title":"Clin Exp Vaccine Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00035.2015","article-title":"Sex and gender impact immune responses to vaccines among the elderly","volume":"30","author":"Fink AL","year":"2015","unstructured":"Fink AL, Klein SL. Sex and gender impact immune responses to vaccines among the elderly. Physiology (Bethesda). 2015, 30:408-16. 10.1152\/physiol.00035.2015","journal-title":"Physiology (Bethesda)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cophys.2018.03.010","article-title":"The evolution of greater humoral immunity in females than males: implications for vaccine efficacy","volume":"6","author":"Fink AL","year":"2018","unstructured":"Fink AL, Klein SL. The evolution of greater humoral immunity in females than males: implications for vaccine efficacy. Curr Opin Physiol. 2018, 6:16-20. 10.1016\/j.cophys.2018.03.010","journal-title":"Curr Opin Physiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-018-0726-5","article-title":"Sex differences in vaccine-induced humoral immunity","volume":"41","author":"Fischinger S","year":"2019","unstructured":"Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019, 41:239-49. 10.1007\/s00281-018-0726-5","journal-title":"Semin Immunopathol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and gender differences in the outcomes of vaccination over the life course","volume":"33","author":"Flanagan KL","year":"2017","unstructured":"Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017, 33:577-99. 10.1146\/annurev-cellbio-100616-060718","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon DE","year":"2021","unstructured":"McMahon DE, Amerson E, Rosenbach M, et al.. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021, 85:46-55. 10.1016\/j.jaad.2021.03.092","journal-title":"J Am Acad Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.12.028","article-title":"Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017","volume":"38","author":"Su JR","year":"2020","unstructured":"Su JR, Haber P, Ng CS, Marquez PL, Dores GM, Perez-Vilar S, Cano MV. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017. Vaccine. 2020, 38:1746-52. 10.1016\/j.vaccine.2019.12.028","journal-title":"Vaccine"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13958","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination","volume":"64","author":"Zou H","year":"2023","unstructured":"Zou H, Daveluy S. Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination. Australas J Dermatol. 2023, 64:e1-10. 10.1111\/ajd.13958","journal-title":"Australas J Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/0923-1811(94)00371-k","article-title":"The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan","volume":"9","author":"Ogawa H","year":"1995","unstructured":"Ogawa H, Sakuma M, Morioka S, Kitamura K, Sasai Y, Imamura S, Inaba Y. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci. 1995, 9:136-41. 10.1016\/0923-1811(94)00371-k","journal-title":"J Dermatol Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13079","article-title":"Malignancies in bullous pemphigoid: a controversial association","volume":"43","author":"Balestri R","year":"2016","unstructured":"Balestri R, Magnano M, La Placa M, Patrizi A, Angileri L, Tengattini V, Bardazzi F. Malignancies in bullous pemphigoid: a controversial association. J Dermatol. 2016, 43:125-33. 10.1111\/1346-8138.13079","journal-title":"J Dermatol"},{"key":"ref33","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2230.1996.tb00005.x","article-title":"Bullous pemphigoid--a report of 86 cases from Taiwan","volume":"21","author":"Chang YT","year":"1996","unstructured":"Chang YT, Liu HN, Wong CK. Bullous pemphigoid--a report of 86 cases from Taiwan. Clin Exp Dermatol. 1996, 21:20-2.","journal-title":"Clin Exp Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1990.tb01447.x","article-title":"The association of bullous pemphigoid and malignant disease: a case control study","volume":"123","author":"Venning VA","year":"1990","unstructured":"Venning VA, Wojnarowska F. The association of bullous pemphigoid and malignant disease: a case control study. Br J Dermatol. 1990, 123:439-45. 10.1111\/j.1365-2133.1990.tb01447.x","journal-title":"Br J Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-024-00165-w","article-title":"Dermatological side effects of dipeptidyl peptidase-4 inhibitors in diabetes management: a comprehensive review","volume":"10","author":"Zaresharifi S","year":"2024","unstructured":"Zaresharifi S, Niroomand M, Borran S, Dadkhahfar S. Dermatological side effects of dipeptidyl peptidase-4 inhibitors in diabetes management: a comprehensive review. Clin Diabetes Endocrinol. 2024, 10:6. 10.1186\/s40842-024-00165-w","journal-title":"Clin Diabetes Endocrinol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/s0738-081x(98)00008-x","article-title":"Drug-induced pemphigoid: bullous and cicatricial","volume":"16","author":"Vassileva S","year":"1998","unstructured":"Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin. Dermatol. 1998, 16:379-87. 10.1016\/s0738-081x(98)00008-x","journal-title":"Clin. Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamadermatol.376","article-title":"The associations between bullous pemphigoid and drug use: a UK case-control study","volume":"149","author":"Lloyd-Lavery A","year":"2013","unstructured":"Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol. 2013, 149:58-62. 10.1001\/2013.jamadermatol.376","journal-title":"JAMA Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15433","article-title":"The role of SARS-CoV-2 infection and its vaccines in various types of hair loss","volume":"35","author":"Aryanian Z","year":"2022","unstructured":"Aryanian Z, Balighi K, Hatami P, Afshar ZM, Mohandesi NA. The role of SARS-CoV-2 infection and its vaccines in various types of hair loss. Dermatol Ther. 2022, 35:e15433. 10.1111\/dth.15433","journal-title":"Dermatol Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18491","article-title":"Alopecia areata after COVID-19 infection and vaccination: a cross-sectional analysis","volume":"37","author":"Nguyen B","year":"2023","unstructured":"Nguyen B, Tosti A. Alopecia areata after COVID-19 infection and vaccination: a cross-sectional analysis. J Eur Acad Dermatol Venereol. 2023, 37:e7-8. 10.1111\/jdv.18491","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050502","article-title":"The incidence and severity of post-vaccination reactions after vaccination against COVID-19","volume":"9","author":"J\u0119\u015bkowiak I","year":"2021","unstructured":"J\u0119\u015bkowiak I, Wiatrak B, Grosman-Dziewiszek P, Szel\u0105g A. The incidence and severity of post-vaccination reactions after vaccination against COVID-19. Vaccines (Basel). 2021, 9:502. 10.3390\/vaccines9050502","journal-title":"Vaccines (Basel)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16113","article-title":"Alopecia areata following COVID-19 vaccination: vaccine-induced autoimmunity?","volume":"61","author":"May Lee M","year":"2022","unstructured":"May Lee M, Bertolani M, Pierobon E, Lotti T, Feliciani C, Satolli F. Alopecia areata following COVID-19 vaccination: vaccine-induced autoimmunity?. Int J Dermatol. 2022, 61:634-5. 10.1111\/ijd.16113","journal-title":"Int J Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.11.023","article-title":"Alopecia areata after SARS-CoV-2 vaccination","volume":"20","author":"Scollan ME","year":"2022","unstructured":"Scollan ME, Breneman A, Kinariwalla N, Soliman Y, Youssef S, Bordone LA, Gallitano SM. Alopecia areata after SARS-CoV-2 vaccination. JAAD Case Rep. 2022, 20:1-5. 10.1016\/j.jdcr.2021.11.023","journal-title":"JAAD Case Rep"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-006-0700-2","article-title":"In vivo levels of IL-4, IL-10, TGF-beta1 and IFN-gamma mRNA of the peripheral blood mononuclear cells in patients with alopecia areata in comparison to those in patients with atopic dermatitis","volume":"298","author":"Katagiri K","year":"2007","unstructured":"Katagiri K, Arakawa S, Hatano Y. In vivo levels of IL-4, IL-10, TGF-beta1 and IFN-gamma mRNA of the peripheral blood mononuclear cells in patients with alopecia areata in comparison to those in patients with atopic dermatitis. Arch Dermatol Res. 2007, 298:397-401. 10.1007\/s00403-006-0700-2","journal-title":"Arch Dermatol Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1992.tb03932.x","article-title":"Profile of alopecia areata: a questionnaire analysis of patient and family","volume":"31","author":"Shellow WV","year":"1992","unstructured":"Shellow WV, Edwards JE, Koo JY. Profile of alopecia areata: a questionnaire analysis of patient and family. Int J Dermatol. 1992, 31:186-9. 10.1111\/j.1365-4362.1992.tb03932.x","journal-title":"Int J Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7753.136746","article-title":"A review of psychiatric disorders comorbidities in patients with alopecia areata","volume":"6","author":"Ghanizadeh A","year":"2014","unstructured":"Ghanizadeh A, Ayoobzadehshirazi A. A review of psychiatric disorders comorbidities in patients with alopecia areata. Int J Trichology. 2014, 6:2-4. 10.4103\/0974-7753.136746","journal-title":"Int J Trichology"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02028.x","article-title":"The role of psychological factors in alopecia areata and the impact of the disease on the quality of life","volume":"43","author":"G\u00fcle\u00e7 AT","year":"2004","unstructured":"G\u00fcle\u00e7 AT, Tanriverdi N, D\u00fcr\u00fc C, Saray Y, Ak\u00e7ali C. The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol. 2004, 43:352-6. 10.1111\/j.1365-4632.2004.02028.x","journal-title":"Int J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/346634-cutaneous-adverse-events-following-covid-19-vaccination-in-japan-a-questionnaire-survey","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T17:33:40Z","timestamp":1741455220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/346634-cutaneous-adverse-events-following-covid-19-vaccination-in-japan-a-questionnaire-survey"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.80257","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,8]]}}}